Diarrhea Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 01, 2015 09:08 EST

This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Diarrhea” addition with 54 market data tables and 15 figures, spread across 183 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

A. Menarini Industrie Farmaceutiche Riunite Srl, Ache Laboratorios Farmaceuticos S/A, Actelion Ltd, Aegis Therapeutics, LLC, Akthelia pharmaceuticals ehf, Allergan Plc, Anatara Lifesciences Limited, Ardelyx, Inc., Assembly Biosciences, Inc., Chiesi Farmaceutici SpA, Chongqing Zhifei Biological Products Co., Ltd., Cosmo Pharmaceuticals S.p.A, DesignMedix, Inc., DiscoveryBiomed, Inc., GlaxoSmithKline Plc, GP Pharm, S.A., Helsinn Healthcare S.A., Intercept Pharmaceuticals, Inc., Ipsen S.A., Merck & Co., Inc., Mucosis B.V., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Prokarium Limited, Protagonist Therapeutics Inc., Rebiotix Inc., Sanofi Pasteur SA, Scandinavian Biopharma Holding AB, Shire Plc, Sigmoid Pharma Limited, Summit Therapeutics Plc, Synthetic Biologics, Inc. and Syntiron LLC

Drugs Profile Discussed in this Research:

ACE-527, ACE-920, ACH-04, AKT-10081, ASP-7147, cadazolid, clostridium difficile vaccine, crofelemer DR, diarrhea vaccine, diarrhea vaccine, Drug for Diarrhea, elsiglutide, eluxadoline, Escherichia coli vaccine, ETEC vaccine, Etvax, fidaxomicin, GVXNSD-133, Helicobacter pylori [Hel-305] (multivalent) vaccine, ibodutant, IMSUTMR-1501, infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine, iOWH0-32, lanreotide acetate, MB-101, obeticholic acid, octreotide acetate, octreotide acetate MAR, Peptide for Enterocolitis and Infectious Diarrhea, PF-06425090, prulifloxacin, PZ-7475, RBX-2660, RDX-009, Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea, Recombinant Proteins for Infectious Diarrhea, ridinilazole, rifamycin, Small Molecule for Diarrhea, Small Molecule to Block CFTR for Diarrhoea, Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease, Small Molecules for Diarrhea, Small Molecules for Microbial Infections, Small Molecules to Inhibit CFTR for Secretory Diarrhea, surotomycin, SYN-004, Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea, Typhetec, Vaccine for Campylobacter Caused Diarrhea, Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea, VP-20621 and Yersinia pestis vaccine

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Diarrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diarrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Gastrointestinal therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries